Back

Investigation of the continuous spread of SARS-CoV-2 in the post pandemic time - Insights into the reason for the sustained spread despite the establishment of population immunity

Yi, B.

2026-06-08 epidemiology
10.64898/2026.06.05.26355009 medRxiv
Show abstract

In spite of well-established global immune landscape, SARS-CoV-2 is still able to further spread and continue causing infection waves. The current understanding about the reason behind is limited, and it is still difficult to predict the evolution or spreading tread of SARS-CoV-2. Therefore, it is necessary to investigate whether the establishment of population immunity has changed the virus evolution or spreading pattern. In this investigation, one overall analysis of the SARS-CoV-2 spreading in the past several years have been carried out through one thorough genomic epidemiology study, with Germany being chosen as one representative location in view of the systemic efforts for genomic surveillance. The growth advantage of a few predominant variants in its early spreading period has been evaluated through a logistic regression model. The results have revealed that the major circulating SARS-CoV-2 variants since 2023 are mainly derived from the Omicron BA.2 family. Since middle of 2024, most predominant variants were produced primarily through recombination, indicating that the evolution derived from recombination might be the major driving force for the continuous spread of SARS-CoV-2 despite the existence of population immunity. Furthermore, the lower growth advantage of recently emerged variants might possibly lead to a tread of reduction in the frequency of infection wave. The information revealed from this investigation suggests that although short-term spreading tread can be affected by specific virus feature as well as local immunity landscape, the long-term spreading tread is mainly decided by the genomic diversity of the viruses, and can be predicted through phylogenetic and genomic epidemiology investigation. The results have emphasized the importance of maintaining the efforts for genomic surveillance of SARS-CoV-2, which is essential from both medical and research perspectives.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

1
Journal of Medical Virology
137 papers in training set
Top 0.1%
10.0%
2
PLOS ONE
4510 papers in training set
Top 20%
9.0%
3
Frontiers in Public Health
140 papers in training set
Top 0.3%
9.0%
4
Scientific Reports
3102 papers in training set
Top 19%
6.3%
5
Viruses
318 papers in training set
Top 0.9%
6.2%
6
Frontiers in Medicine
113 papers in training set
Top 0.8%
4.8%
7
Virus Research
36 papers in training set
Top 0.1%
4.1%
8
Epidemiology and Infection
84 papers in training set
Top 0.5%
3.6%
50% of probability mass above
9
Biology
43 papers in training set
Top 0.2%
3.5%
10
Gene
41 papers in training set
Top 0.4%
2.8%
11
Infection, Genetics and Evolution
43 papers in training set
Top 0.2%
2.7%
12
Emerging Microbes & Infections
74 papers in training set
Top 0.6%
2.0%
13
Journal of Clinical Medicine
91 papers in training set
Top 2%
2.0%
14
Frontiers in Microbiology
375 papers in training set
Top 5%
1.9%
15
Archives of Virology
14 papers in training set
Top 0.2%
1.8%
16
PeerJ
261 papers in training set
Top 7%
1.7%
17
Frontiers in Genetics
197 papers in training set
Top 5%
1.7%
18
JMIR Public Health and Surveillance
45 papers in training set
Top 2%
1.5%
19
International Journal of Infectious Diseases
126 papers in training set
Top 2%
1.2%
20
Computers in Biology and Medicine
120 papers in training set
Top 3%
0.9%
21
Computational and Structural Biotechnology Journal
216 papers in training set
Top 8%
0.9%
22
Informatics in Medicine Unlocked
21 papers in training set
Top 0.9%
0.9%
23
Heliyon
146 papers in training set
Top 5%
0.9%
24
Pathogens
53 papers in training set
Top 1%
0.8%
25
Frontiers in Virology
15 papers in training set
Top 0.1%
0.8%
26
mSystems
361 papers in training set
Top 7%
0.8%
27
International Journal of Molecular Sciences
453 papers in training set
Top 16%
0.7%
28
Journal of Infection
71 papers in training set
Top 3%
0.7%
29
Clinical Infectious Diseases
231 papers in training set
Top 5%
0.7%
30
Vaccines
196 papers in training set
Top 3%
0.7%